SARS-CoV-2或MIS-C住院患儿严重神经系统表现与新发功能障碍
这项来自10个国家46个中心的前瞻性队列研究纳入3568例18岁以下因急性SARS-CoV-2或MIS-C住院的患儿,评估住院期间严重神经系统表现与出院时新发神经认知和/或功能障碍的关系。急性SARS-CoV-2患儿中18.0%出现严重神经系统表现,MIS-C患儿中为24.8%。校正危险因素后,有严重神经系统表现的急性SARS-CoV-2患儿(OR 1.85,95%CI 1.27-2.70;P=.001)和MIS-C患儿(OR 2.18,95%CI 1.22-3.89;P=.009)出院时新发神经认知和/或功能障碍的 odds 更高。作者认为这类患儿可能长期受损风险高,可能受益于筛查和早期干预以帮助恢复。
要点
- 急性SARS-CoV-2住院患儿中18.0%(536例)出现严重神经系统表现,MIS-C患儿中为24.8%(146例)。
- 急性SARS-CoV-2幸存者中,有严重神经系统表现者出院时新发神经认知或功能障碍27.7%(n=142),无此表现者14.6%(n=356),P<.001。
- MIS-C幸存者中,有严重神经系统表现者出院时新发神经认知和/或功能障碍28.0%(n=39),无此表现者15.5%(n=68),P=.002。
- 校正危险因素后,有严重神经系统表现的急性SARS-CoV-2患儿出院时新发神经认知和/或功能障碍的 odds 更高(OR 1.85,95%CI 1.27-2.70;P=.001)。
- 校正危险因素后,有严重神经系统表现的MIS-C患儿出院时新发神经认知和/或功能障碍的 odds 更高(OR 2.18,95%CI 1.22-3.89;P=.009)。
适用人群与场景
- 18岁以下因急性SARS-CoV-2或MIS-C住院的患儿,来自10个国家46个中心,入院时间为2020年1月2日至2021年7月31日。
- 总样本3568例,中位年龄8岁(IQR 1-14岁),男性54.3%;其中急性SARS-CoV-2 2980例(83.5%),MIS-C 588例(16.5%)。
研究设计与关键结果
- 研究类型为前瞻性队列研究,纳入46个中心、10个国家、3568例18岁以下因急性SARS-CoV-2或MIS-C住院的患儿。
- 暴露为严重神经系统表现,包括急性脑病、癫痫发作或癫痫持续状态、脑膜炎或脑炎、交感风暴或自主神经功能障碍、心脏骤停、昏迷、谵妄和卒中。
- 主要结局为出院时新发神经认知(基于儿童脑功能分类量表)和/或功能(基于功能状态量表)障碍。
- 急性SARS-CoV-2患儿中536例(18.0%)住院期间出现严重神经系统表现,MIS-C患儿中146例(24.8%)出现。
- 急性SARS-CoV-2幸存者中,有严重神经系统表现者出院时新发神经认知或功能障碍27.7%(n=142),无严重神经系统表现者14.6%(n=356),P<.001。
- MIS-C幸存者中,有严重神经系统表现者出院时新发神经认知和/或功能障碍28.0%(n=39),无严重神经系统表现者15.5%(n=68),P=.002。
- 校正危险因素后,有严重神经系统表现的急性SARS-CoV-2患儿出院时新发神经认知和/或功能障碍的 odds 更高(OR 1.85,95%CI 1.27-2.70;P=.001)。
- 校正危险因素后,有严重神经系统表现的MIS-C患儿出院时新发神经认知和/或功能障碍的 odds 更高(OR 2.18,95%CI 1.22-3.89;P=.009)。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,有急性SARS-CoV-2或MIS-C且出现严重神经系统表现的儿童和青少年可能长期受损风险高,可能受益于筛查和早期干预以帮助恢复。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Neurological manifestations during acute SARS-CoV-2-related multisystem inflammatory syndrome in children (MIS-C) are common in hospitalized patients younger than 18 years and may increase risk of new neurocognitive or functional morbidity.
OBJECTIVE: To assess the association of severe neurological manifestations during a SARS-CoV-2-related hospital admission with new neurocognitive or functional morbidities at discharge.
DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study from 46 centers in 10 countries included patients younger than 18 years who were hospitalized for acute SARS-CoV-2 or MIS-C between January 2, 2020, and July 31, 2021.
EXPOSURE: Severe neurological manifestations, which included acute encephalopathy, seizures or status epilepticus, meningitis or encephalitis, sympathetic storming or dysautonomia, cardiac arrest, coma, delirium, and stroke.
MAIN OUTCOMES AND MEASURES: The primary outcome was new neurocognitive (based on the Pediatric Cerebral Performance Category scale) and/or functional (based on the Functional Status Scale) morbidity at hospital discharge. Multivariable logistic regression analyses were performed to examine the association of severe neurological manifestations with new morbidity in each SARS-CoV-2-related condition.
RESULTS: Overall, 3568 patients younger than 18 years (median age, 8 years [IQR, 1-14 years]; 54.3% male) were included in this study. Most (2980 [83.5%]) had acute SARS-CoV-2; the remainder (588 [16.5%]) had MIS-C. Among the patients with acute SARS-CoV-2, 536 (18.0%) had a severe neurological manifestation during hospitalization, as did 146 patients with MIS-C (24.8%). Among survivors with acute SARS-CoV-2, those with severe neurological manifestations were more likely to have new neurocognitive or functional morbidity at hospital discharge compared with those without severe neurological manifestations (27.7% [n = 142] vs 14.6% [n = 356]; P < .001). For survivors with MIS-C, 28.0% (n = 39) with severe neurological manifestations had new neurocognitive and/or functional morbidity at hospital discharge compared with 15.5% (n = 68) of those without severe neurological manifestations (P = .002). When adjusting for risk factors in those with severe neurological manifestations, both patients with acute SARS-CoV-2 (odds ratio, 1.85 [95% CI, 1.27-2.70]; P = .001) and those with MIS-C (odds ratio, 2.18 [95% CI, 1.22-3.89]; P = .009) had higher odds of having new neurocognitive and/or functional morbidity at hospital discharge.
CONCLUSIONS AND RELEVANCE: The results of this study suggest that children and adolescents with acute SARS-CoV-2 or MIS-C and severe neurological manifestations may be at high risk for long-term impairment and may benefit from screening and early intervention to assist recovery.
参考来源
- Francoeur C, Alcamo AM, Robertson CL, et al. Severe Pediatric Neurological Manifestations With SARS-CoV-2 or MIS-C Hospitalization and New Morbidity. JAMA Netw Open. 2024. PMID: 38857050. doi:10.1001/jamanetworkopen.2024.14122
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。